Eledon Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Eledon Pharmaceuticals, Inc. (Nasdaq: ELDN) on January 2, 2026, reporting an event that occurred on December 30, 2025. The filing details a specific corporate transaction involving the exchange of equity securities.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or debt levels. The document focuses exclusively on a capital structure transaction.
Material Changes
On December 30, 2025, the Company entered into an exchange agreement with Coastlands Capital Partners LP. Under this agreement:
- Coastlands Capital Partners LP exchanged 4,203,764 shares of the Company's common stock for a pre-funded warrant (the "Exchange Warrant").
- The Exchange Warrant allows the purchase of up to 4,203,764 shares of Common Stock.
- The initial exercise price of the Exchange Warrant is $0.001 per share.
- The warrant is exercisable immediately and remains exercisable until fully exercised.
- The transaction was executed in reliance on the exemption from registration under Section 3(a)(9) of the Securities Act of 1933.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. The primary risk factor disclosed relates to beneficial ownership limitations:
- The Holder may not exercise the warrant if doing so would cause them to beneficially own more than 4.99% of the outstanding Common Stock.
- This limitation may be increased by the Holder upon 61 days' prior notice, subject to a maximum cap of 19.99% as required by Nasdaq Marketplace Rules.
Key Facts for Investor Verification
- Verify the total number of shares outstanding immediately following the exchange to calculate the precise impact of the 4.99% and 19.99% beneficial ownership caps.
- Confirm the terms of the Exchange Warrant in Exhibit 4.1, specifically regarding adjustment mechanisms for the exercise price.
- Review the Company's most recent 10-Q or 10-K for current cash position and liquidity status, as this 8-K does not disclose financial condition.
- Monitor future filings for any notices from Coastlands Capital Partners LP regarding an increase in the beneficial ownership limitation.